Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Februar 2019 08:27 ET | Quelle: Cerecor, Inc.

Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency

ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
15. Februar 2019 06:30 ET | Quelle: Cerecor, Inc.

Cerecor Announces CERC-301 Granted U.S. Patent

ROCKVILLE, Md., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and...
28. Januar 2019 06:30 ET | Quelle: Cerecor, Inc.

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

ROCKVILLE, Md., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and...
22. Januar 2019 06:30 ET | Quelle: Cerecor, Inc.

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
16. Januar 2019 06:30 ET | Quelle: Cerecor, Inc.

FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and...
13. November 2018 07:00 ET | Quelle: Cerecor, Inc.

Cerecor Reports Third Quarter 2018 Results

BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and...
31. Oktober 2018 16:00 ET | Quelle: Cerecor, Inc.

Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

BALTIMORE, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and...
30. Oktober 2018 16:00 ET | Quelle: Cerecor, Inc.

Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism

BALTIMORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and...
26. September 2018 13:00 ET | Quelle: Cerecor, Inc.

Cerecor to Participate in Upcoming Healthcare Conferences

BALTIMORE, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today...
25. September 2018 06:30 ET | Quelle: Cerecor, Inc.

Cerecor to Acquire Ichorion Therapeutics

Transaction worth approximately $26.6 Million in Stock Plus Potential Milestones Accelerates Cerecor’s Transformation Strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio ...

Nächste Seite